Wilson Sonsini Goodrich & Rosati advised Kumquat Biosciences on the transaction. Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced a strategic and...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Kumquat Biosciences on the transaction. Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced a strategic and...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Exelixis, Inc. and Insilico Medicine announced that they have entered into an exclusive license agreement granting Exelixis...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced a multi-year, multi-target strategic research...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised LaNova on the deal. Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel targeted therapies for...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Temasek on the deal. UPSIDE Foods (formerly Memphis Meats), a leading company in the cultivated meat, poultry, and seafood industry, announced the close...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised EQRx in the deal while Wilson Sonsini Goodrich & Rosati represented InSilico. EQRx annlounced a strategic collaboration with Insilico Medicine to jointly...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the deal. Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading innovation-driven international healthcare group in China, and...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised InSilico Medicine on the deal. Ashurst represented Mirae Asset Capital. Hong Kong-based InSilico Medicine, a global leader in end-to-end artificial...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Lilly Asia Ventures on the deal. Regor Therapeutics, a clinical-stage biotechnology company dedicated to the discovery of innovative medicines to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised WuXi AppTec on the deal. WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in...
You must be a Standard 1 Year member to access this content.
